The AS-AQ Dose Impact Study Group formed in October 2011, with an open invitation to interested researchers with relevant data sets. Potential study group participants met at the December 2011 ASTMH Annual Meeting to discuss the Study Group governance and publication policy. The study group closed in March 2013. The latest results were presented at the 2014 RSTMH biannual Meeting in Oxford, UK.
The Study Group pooled 45 studies (10,821 patients) conducted between 1999 and 2012. This includes nine unpublished studies and 36 published studies representing 65% of the targeted published literature on this treatment regimen. Out of the 45 studies, 43 (9,106 patients) were included in the final analysis. Of those patients included in the final analysis, 93.7% were from Africa, 5.7% from Asia and 0.5% from South America.
The publication: The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data was published in March 2015
Download a presentation from the AS-AQ Dose Impact Study Group.